JP2011525502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525502A5 JP2011525502A5 JP2011515144A JP2011515144A JP2011525502A5 JP 2011525502 A5 JP2011525502 A5 JP 2011525502A5 JP 2011515144 A JP2011515144 A JP 2011515144A JP 2011515144 A JP2011515144 A JP 2011515144A JP 2011525502 A5 JP2011525502 A5 JP 2011525502A5
- Authority
- JP
- Japan
- Prior art keywords
- het
- disease
- atoms
- group
- stereoisomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 31
- 150000003839 salts Chemical class 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 201000004681 Psoriasis Diseases 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 208000022461 Glomerular disease Diseases 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- -1 penta-substituted phenyl Chemical group 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010011017 Corneal graft rejection Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 241001364096 Pachycephalidae Species 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 208000002849 chondrocalcinosis Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 231100000852 glomerular disease Toxicity 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 201000003142 neovascular glaucoma Diseases 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
- 238000004517 catalytic hydrocracking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008029734.8 | 2008-06-23 | ||
| DE102008029734A DE102008029734A1 (de) | 2008-06-23 | 2008-06-23 | Thiazolyl-piperidinderivate |
| PCT/EP2009/003817 WO2009156041A2 (de) | 2008-06-23 | 2009-05-28 | Thiazolyl-piperidinderivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525502A JP2011525502A (ja) | 2011-09-22 |
| JP2011525502A5 true JP2011525502A5 (enExample) | 2012-07-12 |
| JP5607038B2 JP5607038B2 (ja) | 2014-10-15 |
Family
ID=41335014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515144A Expired - Fee Related JP5607038B2 (ja) | 2008-06-23 | 2009-05-28 | チアゾリルピペリジン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8436186B2 (enExample) |
| EP (1) | EP2313403B1 (enExample) |
| JP (1) | JP5607038B2 (enExample) |
| KR (1) | KR20110031349A (enExample) |
| CN (1) | CN102066367A (enExample) |
| AR (1) | AR072192A1 (enExample) |
| AU (1) | AU2009262631B2 (enExample) |
| BR (1) | BRPI0913234A2 (enExample) |
| CA (1) | CA2728851A1 (enExample) |
| DE (1) | DE102008029734A1 (enExample) |
| EA (1) | EA201100035A1 (enExample) |
| IL (1) | IL210164A0 (enExample) |
| MX (1) | MX2010013915A (enExample) |
| WO (1) | WO2009156041A2 (enExample) |
| ZA (1) | ZA201100566B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0811978A2 (pt) * | 2007-06-01 | 2014-11-18 | Hoffmann La Roche | Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e uso dos compostos |
| AU2010341229A1 (en) * | 2009-12-17 | 2012-08-02 | Merck Patent Gmbh | Sphingosine kinase inhibitors |
| CA2806734A1 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| GB201020161D0 (en) | 2010-11-26 | 2011-01-12 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB2493142A (en) | 2011-07-20 | 2013-01-30 | Johann Wolfgang Goethe Uni T Frankfurt | Ceramide and ceramide synthase in the diagnosis and treatment of multiple sclerosis |
| CN104144927B (zh) * | 2011-12-23 | 2016-08-24 | 明治制果药业株式会社 | S1p受体调节剂 |
| EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS |
| WO2014157382A1 (ja) * | 2013-03-29 | 2014-10-02 | 味の素株式会社 | スフィンゴシンキナーゼ阻害剤 |
| CN113826612B (zh) | 2014-06-10 | 2022-11-22 | 生物马特里卡公司 | 在环境温度下稳定凝血细胞 |
| WO2016019312A2 (en) * | 2014-07-31 | 2016-02-04 | Oregon Health & Science University | Vmat inhibitory compounds |
| WO2016085933A1 (en) | 2014-11-24 | 2016-06-02 | The Board Of Trustees Of The University Of Illinois | Method of preventing or treating a pulmonary disease or condition |
| BR112018011639A2 (pt) | 2015-12-08 | 2018-11-27 | Biomatrica Inc | redução de taxa de sedimentação de eritrócitos |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | ４―アニリノキナゾリン誘導体 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| CA2410562A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| CA2613122C (en) | 2005-06-29 | 2013-01-22 | Compumedics Limited | Sensor assembly with conductive bridge |
| CA2617788A1 (en) | 2005-08-04 | 2007-02-15 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitors and methods of their use |
| EP1945635B1 (en) | 2005-08-18 | 2009-05-06 | F.Hoffmann-La Roche Ag | Thiazolyl piperidine derivatives useful as h3 receptor modulators |
| WO2007064553A2 (en) | 2005-11-29 | 2007-06-07 | Merck & Co., Inc. | Thiazole derivatives as cxcr3 receptor modulators |
-
2008
- 2008-06-23 DE DE102008029734A patent/DE102008029734A1/de not_active Withdrawn
-
2009
- 2009-05-28 CN CN2009801234988A patent/CN102066367A/zh active Pending
- 2009-05-28 US US13/000,573 patent/US8436186B2/en not_active Expired - Fee Related
- 2009-05-28 BR BRPI0913234A patent/BRPI0913234A2/pt not_active IP Right Cessation
- 2009-05-28 WO PCT/EP2009/003817 patent/WO2009156041A2/de not_active Ceased
- 2009-05-28 EP EP09768890.7A patent/EP2313403B1/de not_active Not-in-force
- 2009-05-28 EA EA201100035A patent/EA201100035A1/ru unknown
- 2009-05-28 AU AU2009262631A patent/AU2009262631B2/en not_active Ceased
- 2009-05-28 KR KR1020117001604A patent/KR20110031349A/ko not_active Withdrawn
- 2009-05-28 CA CA2728851A patent/CA2728851A1/en not_active Abandoned
- 2009-05-28 MX MX2010013915A patent/MX2010013915A/es not_active Application Discontinuation
- 2009-05-28 JP JP2011515144A patent/JP5607038B2/ja not_active Expired - Fee Related
- 2009-06-19 AR ARP090102229A patent/AR072192A1/es unknown
-
2010
- 2010-12-21 IL IL210164A patent/IL210164A0/en unknown
-
2011
- 2011-01-21 ZA ZA2011/00566A patent/ZA201100566B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525502A5 (enExample) | ||
| JP7146016B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物および組成物 | |
| US11931363B2 (en) | Triazolopyrimidine compounds and uses thereof | |
| JP6994474B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物および組成物 | |
| US10287266B2 (en) | Compounds and compositions for inhibiting the activity of SHP2 | |
| US10676479B2 (en) | Imidazolepyridine compounds and uses thereof | |
| JP2015509512A5 (enExample) | ||
| US10196405B2 (en) | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | |
| BR112020020085A2 (pt) | composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir produção de interferons de tipo i dependentes de sting e para tratar um distúrbio de proliferação celular | |
| JP2016196492A5 (enExample) | ||
| WO2013066835A2 (en) | Compounds and methods | |
| CN102131809A (zh) | 三环吡唑并吡啶激酶抑制剂 | |
| JP2017503000A (ja) | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 | |
| JP2014518884A5 (enExample) | ||
| JP2015515961A5 (enExample) | ||
| US10577362B2 (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| JP2015524450A5 (enExample) | ||
| AU2019385397A1 (en) | Macrocyclic inhibitors of DYRK1A | |
| CA2901155C (en) | Camkii inhibitors and uses thereof | |
| CN102584690A (zh) | 吡啶-2-酮类化合物，其制备方法以及所述吡啶-2-酮类化合物的应用 | |
| CN102858769A (zh) | 吡唑并吡啶激酶抑制剂 | |
| CA3117838A1 (en) | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | |
| AU2022386137A1 (en) | Compositions comprising amino lipid compounds and methods of making and use thereof | |
| CN103003273A (zh) | 吡唑并吡啶激酶抑制剂 | |
| TWI839382B (zh) | 新穎雜環芳香族醯胺衍生物及含有其之醫藥 |